Hershey says GLP-1s are driving higher gum and mint sales

In this article

Hershey

is seeing higher sales for its mints and gum — thanks to the growing use of GLP-1 drugs.

“We’ve also seen strong demand for gum and mints, as the category benefits from functional snacking tailwinds, including GLP-1 adoption,” CEO Kirk Tanner said in pre-recorded remarks ahead of the company’s earnings conference call Thursday. “Retails sales for our third-largest confection brand, Ice Breakers, increased over 8% in the quarter.”

While Tanner didn’t specify why the increasing usage of GLP-1 agonists fueled mint and gum sales, some people who take medications like Ozempic, Wegovy and Mounjaro report experiencing halitosis, or bad breath. However, so-called Ozempic breath is not an official listed side effect for the medication.